|
Security
Type
|
Security Class Title
|
Fee
Calculation
Rule
|
Amount
Registered
(1)
|
Proposed
Maximum
Offering
price
Per Unit
|
Maximum
Aggregate
Offering Price
(2)
|
Fee Rate
|
Amount of
Registration
Fee
|
||||||||||
|
Equity
|
Common Stock, par value $0.0001 per share, to be issued under the Ocuphire Pharma, Inc. 2021 Inducement Plan
|
Other (2)
|
2,000,000 (3)
|
|
$2.945 (2)
|
|
$0.00014760
|
||||||||||
|
Total Offering Amounts
|
|
$5,890,000
|
$869.36
|
||||||||||||||
|
Total Fee Offsets
|
|
$0.00
|
|||||||||||||||
|
Net Fee Due
|
|
$869.36
|
| (1) |
Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, (the “Securities Act”), this Registration Statement shall also cover
any additional shares of Ocuphire Pharma, Inc. (the “Registrant”) common stock that become issuable under the Registrant’s 2021 Inducement Plan (the “Inducement Plan”) set forth herein by reason of any stock dividend, stock split, reclassification, recapitalization, spin-off or other similar transaction effected without receipt of consideration that increases
the number of outstanding shares of the Registrant’s common stock, as applicable.
|
| (2) |
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act. The offering price per share and aggregate offering price are
based on the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Capital Market on November 17, 2023.
|
| (3) |
Represents 2,000,000 shares reserved for grant under the Inducement Plan pursuant to a First Amendment to the Inducement Plan that was approved by the Registrant’s board of
directors on October 30, 2023.
|